Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report

Modern treatment of patients with oncohematological diseases has allowed to achieve remission or even convalescence in many cases. One of ambitious aims put forward by the hematological society is 100% survival and preservation of quality of life in patients with chronic myeloid leukemia (CML). This hope is related with the emergence of targeted therapy for CML. The second-generation tyrosine kinase inhibitor, dasatinib, which is used for treatment of CML, can occasionally induce severe pulmonary hypertension (PH). We presented here a case report of such cardiotoxicity, which was evident as PH and heart failure in a young female patient with CML treated with dasatinib. Information from published reports about this type of cardiotoxicity is provided. At present time, dasatinib is beginning to be extensively used also in other oncological diseases. For this reason, cardiologists and physicians should be aware of this cardiotoxicity, which can cause heart failure in dasatinib-treated patients.

онкогематологические заболевания, кардиотоксичность, дазатиниб, легочная артериальная гипертензия, oncohematological diseases, cardiotoxicity, dasatinib, pulmonary arterial hypertension

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, ApperleyJ et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27 (35):6041-51. DOI:10.1200/JCO. 2009.25.0779.

2. Galiè N, Humbert M, VachieryJ-L, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37 (1):67-119. D OI : 10.1093 / eurheartj / ehv317.

3. Hennigs JK, Keller G, Baumann HJ, Honecker F, Kluge S, Bokemeyer C et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011; 11:30. DOI: 10.1186/1471-2466-11-30.

4. Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci. 2001;321 (4):292-9.

5. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125 (17):2128-37. DOI:10.1161/ CIRCULATIONAHA. 111.079921.

6. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110 (12):4055-63. DOI:10.1182/ blood-2007-07-102061.

7. Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43 (12):967-8. DOI:10.1038/bmt. 2008.415.

8. Groeneveldt JA, Gans SJM, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J. 2013;42 (3):869-70. DOI:10.1 183/09031936.00035913.

9. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33 (6):861-4. DOI:10.1016/ j. leukres. 2008.09.026.

10. de Jesus Perez V, Kudelko K, Snook S, Zamanian RT. Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead. Int J Clin Pract Suppl. 2011; (169):8-10. DOI: 10.1111 /j. 1742-1241.2010.02606. x

11. Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90 (11): 1060-4. DOI: 10.1002/ajh. 24174

12. Quintas-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25 (25):3908-14. DOI:10.1200/JCO. 2007.12.0329.

13. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur RespirJ. 2011;38 (1):218-20. DOI:10.1183/09031936.00154210.

14. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36 (1):e4-6. DOI:10.1016/j. leukres. 2011.08.007.

15. Breccia M, Efficace F, Alimena G. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf? Leuk Res. 2012;36 (7):813-4. DOI:10.1016/j. leukres. 2012.03.010.

16. Weatherald J, Chaumais M-C, Montani D. Pulmonary arterial hypertension induced by tyrosine kinase inhibitors. Curr Opin Pulm Med. 2017;23 (5):392-7. DOI:10.1097/MCP. 0000000000000412.

17. Емелина Е. И., Шуйкова К. В., Гендлин Г. Е., Сторожаков Г. И., Лепков С. В., Демина Е. А. Поражение сердца при лечении современными противоопухолевыми препаратами и лучевые повреждения сердца у больных с лимфомами. Клиническая онкогематология Фундаментальные исследования и клиническая практика. 2009;2 (2):152-60 [Emelina E. I., Shujkova K. V., Gendlin G. E., Storozhakov G. I., Lepkov S. V., Demina E. A. Porazhenie serdcza pri lechenii sovremenny'mi protivoopuxolevy'mi preparatami i luchevy'e povrezhdeniya serdcza u bol'ny'x s limfomami. Klinicheskaya onkogematologiya Fundamental'ny'e issledovaniya i klinicheskaya praktika. 2009;2 (2):152-60].

18. Гендлин Г. Е., Сторожаков Г. И., Шуйкова К. В., Емелина Е. И., Клюшина Г. М., Миронков А. Б. и др. Острые сердечно-сосудистые события во время применения противоопухолевых химиопрепаратов: клинические наблюдения. Клиническая онкогематология Фундаментальные исследования и клиническая практика. 2011;4 (2):155-64 [Gendlin G. E., Storozhakov G. I., Shujkova K. V., Emelina E. I., Klyushina G. M., Mironkov A. B. i dr. Ostry'e serdechno-sosudisty'e soby'tiya vo vremya primeneniya protivoopuxolevy'x ximiopreparatov: klinicheskie nablyudeniya. Klinicheskaya onkogematologiya Fundamental'ny'e issledovaniya i klinicheskaya praktika. 2011;4 (2):155-64].

19. Гендлин Г. Е., Сторожаков Г. И., Макеева Л. М., Емелина Е. И., Шуйкова К. В. Кардиоваскулярные осложнения при лечении хронического миелолейкоза ингибиторами тирозинкиназы. Клиническая онкогематология Фундаментальные исследования и клиническая практика. 2013;6 (1):78-83 [Gendlin G. E., Storozhakov G. I., Makeeva L. M., Emelina E. I., Shujkova K. V. Kardiovaskulyarny' e oslozhneniya pri lechenii xronicheskogo mielolejkoza ingibitorami tirozinkinazy'. Klinicheskaya onkogematologiya Fundamental'ny'e issledovaniya i klinicheskaya praktika. 2013;6 (1):78-83].

20. An X, Tiwari AK, Sun Y, Ding P-R, Ashby CR, Chen Z-S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34 (10):1255-68. DOI:10.1016/j. leukres. 2010.04.016.

21. Baliga RS, MacAllister RJ, Hobbs AJ. New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol. 2011;163 (1):125-40. DOI:10.1111/j. 1476-5381.2010.01164. x

22. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43 (12 Suppl S): 13S-24S. DOI:10.1016/j. jacc. 2004.02.029

23. Nagaraj C, Tang B, Balint Z, Wygrecka M, Hrzenjak A, Kwapiszewska G et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J. 2013;41 (1):85-95. DOI: 10.1183/09031936.00211811

24. Levin YD, White RJ. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil. Drugs Today. 2011;47 (2):145-56.DOI:10.1358/dot. 2011.47.2.1544337

25. Baumgart B, Guha M, Hennan J, Li J, Woicke J, Simic D et al. In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension. Cancer Chemother Pharmacol. 2017;79 (4):711-23. DOI:10.1007/s002 80-017-3264-2

26. Данилов Н. М., Мартынюк Т. В., Матчин Ю. Г., Чазова И. Е., Белятко Е. А. Острые фармакологические пробы при легочной гипертензии: оценка эффективности ингаляционного илопроста. Consilium Medicum. 2013; 15 (10):86-90 [Danilov N. M., Marty'nyuk T. V., Matchin Yu. G., Chazova I. E., Belyatko E. A. Ostry'e farmakologicheskie proby' pri legochnoj gipertenzii: oczenka e'ffektivnosti ingalyaczionnogo iloprosta. Consilium Medicum. 2013;15 (10):86-90]

27. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14 (13):1307-16. DOI: 10.1016/S 1470-2045 (13) 70479-0

28. Parseghian CM, Parikh NU, Wu JY, Jiang Z-Q, Henderson L, Tian F et al. Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23 (15):4146 54. DOI:10.1158/1078-0432. CCR-16-3138